OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial
OncoMed announced the first patient has been dosed in the company's Phase 1a clinical trial of GITRL-Fc (OMP-336B11). GITRL-Fc is an investigational immuno-oncology therapeutic candidate designed to leverage the natural trimeric ligand to modulate the tumor microenvironment. September 13, 2017